Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaPP3 aspirin dose study in Lynch syndrome
ACTRN12617000804381Phase 3Completed
- Sponsor
- Royal Melbourne Hospital
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in hereditary nonpolyposis colorectal cancer (HNPCC) and cancer (3 arms), sponsored by Royal Melbourne Hospital. Primary endpoint: New primary mismatch repair deficient cancers. Started May 2017; status: completed.
02
Drugs
aspirin
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)cancer
Beyond the preview
Go deeper on ACTRN12617000804381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000804381.